These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 34193864)

  • 21. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.
    McEvoy NL; Clarke JL; Mc Elvaney OJ; Mc Elvaney OF; Boland F; Hyland D; Geoghegan P; Donnelly K; Friel O; Cullen A; Collins AM; Fraughen D; Martin-Loeches I; Hennessy M; Laffey JG; Mc Elvaney NG; Curley GF
    Trials; 2021 Apr; 22(1):288. PubMed ID: 33874981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
    Lanzoni G; Linetsky E; Correa D; Messinger Cayetano S; Alvarez RA; Kouroupis D; Alvarez Gil A; Poggioli R; Ruiz P; Marttos AC; Hirani K; Bell CA; Kusack H; Rafkin L; Baidal D; Pastewski A; Gawri K; Leñero C; Mantero AMA; Metalonis SW; Wang X; Roque L; Masters B; Kenyon NS; Ginzburg E; Xu X; Tan J; Caplan AI; Glassberg MK; Alejandro R; Ricordi C
    Stem Cells Transl Med; 2021 May; 10(5):660-673. PubMed ID: 33400390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigational Use of Mesenchymal Stem/Stromal Cells and Their Secretome as Add-On Therapy in Severe Respiratory Virus Infections: Challenges and Perspectives.
    Mattoli S; Schmidt M
    Adv Ther; 2023 Jun; 40(6):2626-2692. PubMed ID: 37069355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial.
    Kaffash Farkhad N; Sedaghat A; Reihani H; Adhami Moghadam A; Bagheri Moghadam A; Khadem Ghaebi N; Khodadoust MA; Ganjali R; Tafreshian AR; Tavakol-Afshari J
    Stem Cell Res Ther; 2022 Jun; 13(1):283. PubMed ID: 35765103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect.
    Can A; Coskun H
    Stem Cells Transl Med; 2020 Nov; 9(11):1287-1302. PubMed ID: 32779878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of RCTs Pooling Evidence on Mesenchymal Stem Cell (MSC) Therapeutic Applications During COVID-19 Epidemic: A Systematic Review.
    Kandula UR; Wake AD
    Biologics; 2023; 17():85-112. PubMed ID: 37223116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Effectiveness of Intravascular Mesenchymal Stem Cells to Treat Organ Failure and Possible Application in COVID-19 Complications.
    Atluri S; Manocha V; Boddu N; Bhati S; Syed Z; Diwan S; Manchikanti L
    Pain Physician; 2020 Aug; 23(4S):S391-S420. PubMed ID: 32942796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mesenchymal stromal cells as a therapeutic intervention for COVID-19: a living systematic review and meta-analysis protocol.
    Kirkham AM; Monaghan M; Bailey AJM; Shorr R; Lalu MM; Fergusson DA; Allan DS
    Syst Rev; 2021 Sep; 10(1):249. PubMed ID: 34526123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of Trials Currently Testing Stem Cells for Treatment of Respiratory Diseases: Facts Known to Date and Possible Applications to COVID-19.
    Majolo F; da Silva GL; Vieira L; Timmers LFSM; Laufer S; Goettert MI
    Stem Cell Rev Rep; 2021 Feb; 17(1):44-55. PubMed ID: 32827081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial.
    Grégoire C; Layios N; Lambermont B; Lechanteur C; Briquet A; Bettonville V; Baudoux E; Thys M; Dardenne N; Misset B; Beguin Y
    Front Immunol; 2022; 13():932360. PubMed ID: 35860245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS.
    Häberle H; Magunia H; Lang P; Gloeckner H; Körner A; Koeppen M; Backchoul T; Malek N; Handgretinger R; Rosenberger P; Mirakaj V
    J Intensive Care Med; 2021 Jun; 36(6):681-688. PubMed ID: 33663244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring the Immunomodulatory Aspect of Mesenchymal Stem Cells for Treatment of Severe Coronavirus Disease 19.
    Chaudhary JK; Saini D; Chaudhary PK; Maurya A; Verma GK; Gupta AK; Roshan R; Vats TK; Garg N; Yadav D; Kant N; Meena AK; Mirza-Shariff AA
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of MSC Therapy in Attenuating the Damaging Effects of the Cytokine Storm Induced by COVID-19 on the Heart and Cardiovascular System.
    Ellison-Hughes GM; Colley L; O'Brien KA; Roberts KA; Agbaedeng TA; Ross MD
    Front Cardiovasc Med; 2020; 7():602183. PubMed ID: 33363221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics.
    Yadav P; Vats R; Bano A; Bhardwaj R
    Life Sci; 2020 Dec; 263():118588. PubMed ID: 33049279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases.
    Tsuchiya A; Takeuchi S; Iwasawa T; Kumagai M; Sato T; Motegi S; Ishii Y; Koseki Y; Tomiyoshi K; Natsui K; Takeda N; Yoshida Y; Yamazaki F; Kojima Y; Watanabe Y; Kimura N; Tominaga K; Kamimura H; Takamura M; Terai S
    Inflamm Regen; 2020; 40():14. PubMed ID: 32582401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mesenchymal stem cells and their derived exosomes for the treatment of COVID-19.
    Hou XY; Danzeng LM; Wu YL; Ma QH; Yu Z; Li MY; Li LS
    World J Stem Cells; 2024 Apr; 16(4):353-374. PubMed ID: 38690515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy.
    Moll G; Drzeniek N; Kamhieh-Milz J; Geissler S; Volk HD; Reinke P
    Front Immunol; 2020; 11():1091. PubMed ID: 32574263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic mechanisms of mesenchymal stem cells in acute respiratory distress syndrome reveal potentials for Covid-19 treatment.
    Wang W; Lei W; Jiang L; Gao S; Hu S; Zhao ZG; Niu CY; Zhao ZA
    J Transl Med; 2021 May; 19(1):198. PubMed ID: 33971907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overview of Stem Cell Therapy for Acute Respiratory Distress Syndrome with Focus on COVID 19.
    Kaye RJ
    Pain Physician; 2020 Aug; 23(4S):S421-S432. PubMed ID: 32942797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mesenchymal stem cells and their derived exosomes to combat Covid-19.
    Yousefi Dehbidi M; Goodarzi N; Azhdari MH; Doroudian M
    Rev Med Virol; 2022 Mar; 32(2):e2281. PubMed ID: 34363275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.